F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comNeuland Laboratories Ltd, a Hyderabad-based pharmaceutical company, has established itself as a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates. Known for its research-driven approach, high-quality manufacturing facilities, and a strong global client base, the company has been gaining investor attention in the stock market.
In this article, we’ll explore Neuland Laboratories’ share price targets from 2025 to 2030, along with insights into its financial performance, shareholding pattern, and investment advice.
Here are the key details of Neuland Laboratories Ltd’s stock performance and valuation:
| Detail | Value |
|---|---|
| Open | ₹15,015.00 |
| Previous Close | ₹14,803.00 |
| Day’s High | ₹15,760.00 |
| Day’s Low | ₹14,900.00 |
| VWAP | ₹15,310.58 |
| Volume | 1,11,370 |
| Value (₹ Lacs) | 17,409.36 |
| Market Cap (₹ Cr.) | 20,055 |
| Beta | 1.08 |
| 52-Week High | ₹18,100.00 |
| 52-Week Low | ₹10,190.70 |
| UC Limit | ₹17,763.00 |
| LC Limit | ₹11,843.00 |
| All-Time High | ₹18,100.00 |
| All-Time Low | ₹25.23 |
| Book Value Per Share | ₹1,087.42 |
| Dividend Yield | 0.08% |
| 20D Avg Volume | 43,690 |
| 20D Avg Delivery (%) | 30.86 |
| Face Value | ₹10 |
From an all-time low of just ₹25.23 to a record high of ₹18,100, Neuland Laboratories has delivered exceptional returns to long-term investors.
Founded in 1984, Neuland Laboratories Ltd focuses on the development, manufacturing, and marketing of APIs and intermediates for regulated markets worldwide. The company serves therapeutic areas such as central nervous system, cardiovascular, respiratory, and anti-infectives.
Strong presence in global API market
Research-driven and innovation-focused operations
Expanding customer base in the US, Europe, and Japan
Robust manufacturing capacity with regulatory approvals
Long-term demand growth in pharma and healthcare sectors
| Investor Type | Holding (%) |
|---|---|
| Retail & Others | 34.07% |
| Promoters | 32.68% |
| Foreign Institutions | 21.69% |
| Mutual Funds | 7.66% |
| Other Domestic Institutions | 3.91% |
The shareholding pattern reflects balanced participation. Promoters hold 32.68%, while strong foreign institutional interest (21.69%) signals confidence in the company’s global growth outlook.
Based on current fundamentals, financial performance, and sectoral growth trends, here are the projected share price targets for Neuland Laboratories Ltd from 2025 to 2030:
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 15,500 | 16,200 |
| 2026 | 17,000 | 18,000 |
| 2027 | 18,500 | 20,200 |
| 2028 | 20,800 | 22,500 |
| 2029 | 23,000 | 25,000 |
| 2030 | 25,500 | 28,000 |
By 2025, Neuland’s stock is expected to remain stable with moderate upside.
Why?
Demand for APIs continues to grow globally
Steady earnings and improving margins
Market cap of over ₹20,000 Cr reflects strength
Investment Advice: Ideal for investors looking for steady medium-term growth.
The stock may cross ₹17,000 levels by 2026.
Why?
Increasing exports to the US and Europe
New product launches in high-demand therapeutic areas
Strong R&D pipeline
Investment Advice: Hold for long-term as global pharma demand is expected to rise.
By 2027, Neuland could enter a stronger growth phase.
Why?
Higher global adoption of APIs
Expansion of manufacturing facilities
Improving return on equity (ROE) and EPS
Investment Advice: Continue accumulating shares during market corrections.
The company may comfortably cross the ₹20,000 mark in 2028.
Why?
Strategic partnerships with global pharma giants
Rising demand for chronic disease APIs
Better operating margins
Investment Advice: Suitable for long-term investors seeking compounding returns.
A strong bull run in pharma stocks could push Neuland higher.
Why?
Continued expansion in international markets
Increasing FII participation
Growing healthcare expenditure in India and abroad
Investment Advice: Strong buy for long-term portfolios.
By 2030, Neuland could emerge as a global leader in API manufacturing.
Why?
Robust fundamentals and international presence
Expanding market cap potential beyond ₹25,000 Cr
Long-term demand for healthcare and medicines
Investment Advice: Excellent for wealth creation and retirement planning.
Yes, Neuland Laboratories Ltd is a strong long-term bet in the pharmaceutical sector. With a track record of massive growth from ₹25.23 (all-time low) to ₹18,100 (all-time high), the company has proven its potential to deliver multi-bagger returns.
Strong promoter and institutional backing
Global presence in regulated markets
Innovation-driven API portfolio
Expanding customer base and product range
High dependency on regulatory approvals
Intense competition in global API industry
Volatility due to global pharma pricing pressures
Neuland Laboratories Ltd has shown exceptional growth in the past and holds strong potential for the future. With solid fundamentals, global presence, and rising demand for APIs, the stock could see significant appreciation by 2030.
Currently trading around ₹15,000, analysts expect Neuland Laboratories Ltd to reach between ₹25,500 and ₹28,000 by 2030. For long-term investors, this stock could be a valuable addition to the portfolio.
1. What is the current share price of Neuland Laboratories Ltd?
As of 2025, the share price is around ₹15,015.
2. What is the 52-week high and low of Neuland Laboratories Ltd?
The 52-week high is ₹18,100 and the low is ₹10,190.70.
3. Who are the major shareholders of Neuland Laboratories Ltd?
Promoters hold 32.68%, while FIIs hold 21.69% and mutual funds 7.66%.
4. What is the expected target for Neuland Laboratories Ltd in 2025?
The target for 2025 is between ₹15,500 and ₹16,200.
5. Can Neuland Laboratories Ltd cross ₹20,000 in the future?
Yes, it is projected to cross ₹20,000 by 2027–2028.
6. What is the long-term target of Neuland Laboratories Ltd by 2030?
The stock may reach between ₹25,500 and ₹28,000 by 2030.
7. Is Neuland Laboratories Ltd a risky stock?
With a beta of 1.08, it has moderate volatility compared to other pharma stocks.
8. Does Neuland Laboratories Ltd give dividends?
Yes, but with a low dividend yield of 0.08%.
9. Is Neuland Laboratories Ltd good for long-term investment?
Yes, due to strong fundamentals, global demand, and institutional confidence.
10. How has Neuland Laboratories performed historically?
It has grown from an all-time low of ₹25.23 to an all-time high of ₹18,100, proving its long-term potential.
???? Disclaimer: This article is for educational purposes only. Stock investments are subject to risks. Please consult your financial advisor before making investment decisions.
Register & Login